Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

NCT01660906 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
39
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bristol-Myers Squibb